摘要
Unprecedented progress has seen made in the last decade in the fi eld of cancer immunotherapy.The recent approval of nivolumab(Opdivo),the fi rst anti-programmed cell death-1(PD-1)antibody,for metastatic melanoma in Japan,marked a milestone in the rapidly advancing fi eld of cancer immunotherapy.Nivolumab together
Unprecedented progress has seen made in the last decade in the field of cancer immunotherapy. The recent approval of nivolumab （Opdivo）, the first anti-programmed cell death-1 （PD-1） antibody, for metastatic melanoma in Japan, marked a milestone in the rapidly advancing field of cancer immunotherapy. Nivolumab together with ipilimumab （Yervoy）, the anti-cytotoxic T-lymphocyte-associated antigen-4 （CTLA-4） antibody, are the first 2 drugs in the class of ＂immune checkpoint inhibitors＂ that have delivered impressive responses in patients with metastatic melanoma and renal cell cancer （RCC） as well as a variety of solid tumors.
